SCHEMBL18967906

SCHEMBL18967906

N=C(N)c1ccc(Cn2ccc3ncccc32)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 5/20 0.63
PLG P00747 2/20 0.56
F10 P00742 2/20 0.47
PRSS1 P07477 2/20 0.47
F2 P00734 1/20 0.47
HDAC1 Q13547 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
CYP11B1 P15538 4/20 0.40
CYP11B2 P19099 4/20 0.40
HTT P42858 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MAPK1 P28482 1/20 0.40
MEN1 O00255 1/20 0.40
TP53 P04637 1/20 0.40
PABPC1 P11940 1/20 0.40
KMT2A Q03164 1/20 0.40
TNF P01375 1/20 0.40
LMNA P02545 1/20 0.40
LOXL2 Q9Y4K0 1/20 0.39
PRSS2 P07478 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18968025 0.83 PLAU (0.43) PLAUPLGF10PRSS1F2
SCHEMBL18977649 0.80 PLAU (0.46) PLAUPLGF10PRSS1F2
SCHEMBL31061608 0.79 CYP11B1 (0.62) CYP11B1CYP11B2HTTSMN1; SMN2MAPK1
SCHEMBL4716978 0.79 CYP11B1 (0.62) CYP11B1CYP11B2HTTSMN1; SMN2MAPK1
SCHEMBL18967494 0.79 PLAU (0.40) PLAUPLGF10PRSS1F2
SCHEMBL18967493 0.79 PLAU (0.39) PLAUPLGF10PRSS1F2
SCHEMBL18939073 0.79 PLAU (0.39) PLAUPLGF10PRSS1F2
SCHEMBL22547753 0.78 CYP11B1 (0.42) HDAC1HDAC6CYP11B1CYP11B2HTT
SCHEMBL18939015 0.78 PLAU (0.41) PLAUPLG
SCHEMBL31621047 0.77 PLAU (1.00) PLAUPLGF10PRSS1F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9751894-B2 Cephem compounds, their production and use NAEJA-RGM PHARMACEUTICALS INC. (CA) 2017-09-05 US disclosed
US-20170166587-A1 CEPHEM COMPOUNDS, THEIR PRODUCTION AND USE NAEJA-RGM PHARMACEUTICALS ULC (CA) 2017-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170166587-A1 CEPHEM COMPOUNDS, THEIR PRODUCTION AND USE CEP170, AADAC, NAA50 PLAU 4395/4885PLG 3373/4885F10 1489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.